查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2137212

SalgramoStim 市場：全球市場預測，2026-2032 年

Sargramostim Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，沙格司亭市場規模將成長至 2,038,090,000 美元，複合年成長率為 13.09%。

主要市場統計數據
基準年 2025 8.611億美元
預計年份：2026年 9.7308億美元
預測年份 2032 2,038,090,000 美元
複合年成長率 (%) 13.09%

沙格司亭：臨床角色與策略背景

沙格司亭是一種重組粒細胞-巨噬細胞集落刺激因子，可促進特定髓系細胞的生成和功能活性。其臨床意義與骨髓功能恢復受損、嗜中性白血球支持、免疫細胞募集以及特殊移植和感染疾病治療方案相關的疾病密切相關。在評估該市​​場時，不僅應關注產品需求，還應關注已批准的適應症、臨床證據、治療途徑、劑量要求、安全性監測和取得條件。

臨床路徑正在重新調整沙格司亭的使用方式。

隨著支持治療、血液學、移植、腫瘤學和免疫學領域的進展，沙格司亭的應用範圍正在改變。治療決策越來越依賴患者的風險、骨髓功能、感染狀況、先前治療史，以及在造血功能恢復與發炎和肺功能等安全性因素之間取得平衡的必要性。儘管有關免疫介導疾病和感染疾病的證據累積可能會拓寬臨床討論的範圍，但監管差異和治療指南的更新將繼續決定其在常規臨床實踐中的應用程度。

人工智慧增強證據效力並協調醫療服務。

人工智慧 (AI) 可透過識別合格的患者、整合縱向實驗室數據、檢測不利事件模式以及改進臨床試驗受試者招募，為沙格司亭相關的研究和治療提供支援。預測模型可以幫助臨床醫生評估骨髓恢復過程並確定監測的優先順序，但其效用取決於具有代表性的資料集、透明的檢驗以及與臨床工作流程的整合。人工智慧是對醫生判斷、藥物安全監測和監管審查的補充，而非替代，尤其是在治療決策涉及複雜的免疫學和感染風險時。

區域差異反映了法規、基礎設施和臨床實踐。

北美地區擁有相對完善的專業醫療基礎設施、結構化的保險報銷流程以及積極的實證醫學研究。歐洲的情況則受到各國醫療體系決策、歐洲層級的監管協調以及指引執行差異的影響。亞太地區擁有先進的移植和腫瘤中心，但在醫療資源取得、生產製造和診斷能力方面存在顯著差異。拉丁美洲的專科醫生數量和獲取條件各不相同。中東地區的醫療體係既有高度發展的轉診網路，也有資源有限的地區；而非洲的醫療資源利用則主要取決於檢查室的可近性、感染控制能力、供應的連續性以及經濟承受能力。在所有地區，適當的患者選擇和用藥後監測仍然是核心挑戰。

東協、金磚國家、歐盟、七國集團、海灣合作理事會和北約等各集團的優先事項各不相同。

東協市場需要一種能夠兼顧不同管理體制、醫療服務能力和採購模式的方法。金磚國家成員國擁有龐大且多元化的病患群體，但其國內生產能力、報銷體系和專科醫療服務能力各不相同。歐盟強調協調一致的監管標準，並輔以國家評估和報銷決策。七國集團（G7）國家通常擁有成熟的臨床基礎設施和強大的實證醫學網路，但在預算編制和治療路徑整合方面仍面臨挑戰。海灣合作理事會（GCC）系統通常依賴集中採購和高度專業化的轉診醫療機構。北約成員國的醫療體系多種多樣，因此，對於專科藥物而言，協調一致的準備、供應彈性和臨床互通性至關重要。

每個國家的實際情況都會影響實施方案和病人就醫途徑。

澳洲和加拿大依賴專業的醫療網路和正式的評估流程。巴西和墨西哥在公共部門提供的專業醫療服務的取得、採購和覆蓋範圍方面存在區域差異。中國和印度在提供先進醫療服務方面的能力不斷增強，但同時也存在顯著的地域和製度差異。日本和韓國擁有先進的臨床體系，並得到結構化法規環境的支持。法國、德國、義大利、西班牙和英國在歐洲內部的報銷機制、醫院採購和臨床指引路徑上存在差異。俄羅斯的營運環境受到當地法規、醫療資源供應和醫療體系狀況的影響。在美國，專科醫生的處方權、支付方的要求、醫院的診療規範以及持續的臨床證據都對醫療服務的可近性產生重大影響。

領導者的優先事項：證據、取得途徑、安全性和韌性

產業領導者應優先考慮針對特定適應症的證據，以明確臨床效益、病患選擇、劑量和安全性監測。與移植、腫瘤、感染疾病和免疫中心建立合作關係可以提高真實世界證據的品質和實用化。准入策略必須涵蓋報銷文件、醫院處方藥清單制定流程、適用的冷鏈和處理要求以及供應連續性。各機構也應建立健全的藥物安全監測系統、透明的人工智慧管治、區域性醫學教育以及具韌性的生產和分銷系統。與臨床醫生、監管機構、支付方和患者群體合作有助於使產品定位與檢驗的臨床需求保持一致。

調查方法：基於證據的臨床和市場促進因素審查。

本執行摘要涵蓋了「沙格司亭」這個市場主題，並從臨床應用、證據建構、監管、醫療基礎設施、市場准入和營運要求等角度對研究結果進行了梳理。摘要採用定性分析方法，避免使用市場估算、預測、市場規模、市場佔有率以及未經證實的數字資料。針對不同地區、群體和國家的具體觀察結果，整合了醫療體系組織結構及其提供專科醫療服務能力方面的既有差異。後續決策應檢驗現行監管文件、治療指南、報銷政策、同儕審查研究以及當地採購條件。

結論：建立系統的證據將決定沙格司亭的角色。

沙格司亭未來的臨床意義取決於血液學、移植、腫瘤學、免疫學及其他已評估醫學領域證據的可靠性和適用性。由於地區和國家差異，法規核准、專家技術、報銷、監測能力和供應可靠性等因素必須全面考慮。那些能夠將嚴謹的證據生成與負責任的人工智慧應用、病患安全體系、公平的准入計畫和營運韌性相結合的領導者，將更有能力支持沙格司亭的合理實施，而不會高估其臨床或商業性價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：沙格司亭市場：依劑型分類

  • 預填充式注射器
  • 單劑量管瓶

第8章：鹽酸索拉莫司汀市場：依給藥途徑分類

  • 靜脈
  • 皮下

第9章：SalgramoStim市場：依治療方法分類

  • 聯合治療
  • 單藥治療

第10章：SalgramoStim市場：依適應症分類

  • 化療引起的嗜中性白血球低下症
  • 感染預防
  • 支持幹細胞移植

第11章：SalgramoStim 市場：依分銷管道分類

  • 醫院藥房
    • 住院藥房
    • 門診藥房
  • 零售藥房

第12章：SalgramoStim 市場：依最終用戶分類

  • 居家照護
  • 醫院
    • 大學醫院
    • 當地醫院
  • 專科診所

第13章：SalgramoStim市場：依病患年齡層別分類

  • 成人
  • 兒童

第14章：薩爾格拉司亭市集：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：SalgramoStim 市場：依集團分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：薩爾格拉司亭市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Amgen Inc.
  • Biocon Ltd.
  • Cadila Healthcare Ltd.
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Partner Therapeutics, Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.

第19章 主要專家

Product Code: MRR-961F26FD8015

The Sargramostim Market is projected to grow by USD 2,038.09 million at a CAGR of 13.09% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 861.10 million
Estimated Year [2026] USD 973.08 million
Forecast Year [2032] USD 2,038.09 million
CAGR (%) 13.09%

Sargramostim: Clinical Role and Strategic Context

Sargramostim is a recombinant granulocyte-macrophage colony-stimulating factor that supports the production and functional activity of selected myeloid cells. Its clinical relevance is linked to conditions involving impaired marrow recovery, neutrophil support, immune-cell mobilization, and specialized transplantation or infectious-disease protocols. Assessment of this market requires attention to approved indications, clinical evidence, treatment pathways, administration requirements, safety monitoring, and access conditions rather than product demand alone.

Clinical Pathways Are Reshaping Sargramostim Use

Sargramostim's position is being shaped by advances in supportive care, hematology, transplantation, oncology, and immunology. Treatment decisions increasingly depend on patient risk, marrow function, infection status, prior therapy, and the need to balance hematologic recovery with inflammatory or pulmonary safety considerations. Evidence development in immune-mediated and infectious conditions may broaden clinical discussion, while regulatory differences and treatment-guideline updates continue to determine where use is incorporated into routine practice.

Artificial Intelligence Strengthens Evidence and Care Coordination

Artificial intelligence can support sargramostim-related research and care by identifying eligible patients, harmonizing longitudinal laboratory data, detecting adverse-event patterns, and improving trial recruitment. Predictive models may help clinicians evaluate marrow-recovery trajectories and prioritize monitoring, but their usefulness depends on representative datasets, transparent validation, and integration with clinical workflows. AI should complement-not replace-physician judgment, pharmacovigilance, and regulatory review, particularly where treatment decisions involve complex immune and infectious risks.

Regional Differences Reflect Regulation, Infrastructure, and Clinical Practice

North America is characterized by comparatively extensive specialist infrastructure, structured reimbursement processes, and active evidence generation. Europe's landscape is influenced by national health-system decisions, European regulatory coordination, and variation in guideline implementation. Asia-Pacific combines advanced transplant and oncology centers with substantial differences in access, manufacturing, and diagnostic capacity. Latin America faces uneven specialist coverage and procurement conditions. Middle East systems vary between highly developed referral networks and capacity constraints, while Africa's use is most sensitive to laboratory access, infection-management capability, supply continuity, and affordability. Across all regions, appropriate patient selection and post-administration monitoring remain central.

Cross-Group Priorities Differ Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets require approaches that account for diverse regulatory systems, health-service capacity, and procurement models. BRICS members combine large and varied patient populations with differing domestic manufacturing, reimbursement, and specialist-care capabilities. The European Union emphasizes coordinated regulatory standards alongside national assessment and reimbursement decisions. G7 countries generally have mature clinical infrastructure and stronger evidence-generation networks, but still face budget and pathway-integration considerations. GCC systems often depend on centralized procurement and advanced referral centers. NATO members span diverse health systems, making harmonized preparedness, supply resilience, and clinical interoperability relevant to specialist medicines.

Country-Level Conditions Shape Adoption and Patient Access

Australia and Canada rely on specialized healthcare networks and formal assessment processes. Brazil and Mexico face regional variation in specialist access, procurement, and public-sector coverage. China and India combine expanding advanced-care capacity with substantial geographic and institutional differences. Japan and South Korea have sophisticated clinical systems supported by structured regulatory environments. France, Germany, Italy, Spain, and the United Kingdom reflect distinct reimbursement, hospital-procurement, and guideline pathways within Europe. Russia's operating environment is influenced by local regulatory, supply, and healthcare-system conditions. In the United States, specialist prescribing, payer requirements, hospital protocols, and ongoing clinical evidence strongly influence utilization.

Priorities for Leaders: Evidence, Access, Safety, and Resilience

Industry leaders should prioritize indication-specific evidence that clarifies clinical benefit, patient selection, dosing, and safety monitoring. Partnerships with transplant, oncology, infectious-disease, and immunology centers can improve real-world evidence quality and implementation. Access strategies should address reimbursement documentation, hospital formulary processes, cold-chain or handling requirements where applicable, and continuity of supply. Organizations should also establish robust pharmacovigilance, transparent AI governance, region-specific medical education, and resilient manufacturing and distribution arrangements. Engagement with clinicians, regulators, payers, and patient communities can help align product positioning with verified clinical needs.

Methodology: Evidence-Based Review of Clinical and Market-Access Drivers

This executive summary uses the supplied market topic-sargramostim-as the scope and organizes findings around clinical use, evidence development, regulation, healthcare infrastructure, access, and operational requirements. Insights are framed qualitatively and avoid market estimates, market sizing, market shares, forecasts, and unsupported numerical claims. Regional, group, and country observations synthesize established differences in healthcare-system organization and specialist-care capacity; detailed decisions should be validated against current regulatory documents, treatment guidelines, reimbursement policies, peer-reviewed studies, and local procurement conditions.

Conclusion: Disciplined Evidence Development Will Define Sargramostim's Role

Sargramostim's future clinical relevance depends on the strength and applicability of evidence across hematology, transplantation, oncology, immunology, and other evaluated care settings. Regional and country differences mean that regulatory approval, specialist expertise, reimbursement, monitoring capacity, and supply reliability must be considered together. Leaders that combine rigorous evidence generation with responsible AI use, patient-safety systems, equitable access planning, and operational resilience will be better positioned to support appropriate adoption without overstating clinical or commercial conclusions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Sargramostim Market, by Dose Form

  • 7.1. Introduction
  • 7.2. Prefilled Syringe
  • 7.3. Single-Dose Vial

8. Sargramostim Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Subcutaneous

9. Sargramostim Market, by Mode Of Therapy

  • 9.1. Introduction
  • 9.2. Combination Therapy
  • 9.3. Monotherapy

10. Sargramostim Market, by Indication

  • 10.1. Introduction
  • 10.2. Chemotherapy-Induced Neutropenia
  • 10.3. Infection Prophylaxis
  • 10.4. Stem Cell Transplant Support

11. Sargramostim Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
    • 11.2.1. Inpatient Pharmacy
    • 11.2.2. Outpatient Pharmacy
  • 11.3. Retail Pharmacy

12. Sargramostim Market, by End User

  • 12.1. Introduction
  • 12.2. Home Care
  • 12.3. Hospital
    • 12.3.1. Academic Hospital
    • 12.3.2. Community Hospital
  • 12.4. Specialty Clinic

13. Sargramostim Market, by Patient Age Group

  • 13.1. Introduction
  • 13.2. Adult
  • 13.3. Pediatric

14. Sargramostim Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. Sargramostim Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. Sargramostim Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Amgen Inc.
  • 18.2. Biocon Ltd.
  • 18.3. Cadila Healthcare Ltd.
  • 18.4. Celltrion, Inc.
  • 18.5. Dr. Reddy's Laboratories Ltd.
  • 18.6. Fresenius Kabi AG
  • 18.7. Intas Pharmaceuticals Ltd.
  • 18.8. Partner Therapeutics, Inc.
  • 18.9. Sandoz International GmbH
  • 18.10. Teva Pharmaceutical Industries Ltd.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Sargramostim Market, Years Considered for the Study
  • FIGURE 2. Global Sargramostim Market, Research Design
  • FIGURE 3. Global Sargramostim Market, Research Framework
  • FIGURE 4. Global Sargramostim Market, Data Triangulation
  • FIGURE 5. Global Sargramostim Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Sargramostim Market Size, by Dose Form, 2025 vs 2032 (%)
  • FIGURE 7. Global Sargramostim Market Size, by Dose Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Sargramostim Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global Sargramostim Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Sargramostim Market Size, by Mode Of Therapy, 2025 vs 2032 (%)
  • FIGURE 11. Global Sargramostim Market Size, by Mode Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Sargramostim Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 13. Global Sargramostim Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Sargramostim Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 15. Global Sargramostim Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Sargramostim Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global Sargramostim Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Sargramostim Market Size, by Patient Age Group, 2025 vs 2032 (%)
  • FIGURE 19. Global Sargramostim Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Sargramostim Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Sargramostim Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Sargramostim Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Sargramostim Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Sargramostim Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Sargramostim Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Sargramostim Market Segmentation & Coverage
  • TABLE 2. Global Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 4. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Single-Dose Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Single-Dose Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Single-Dose Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 11. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 18. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 19. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 20. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 21. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 25. Global Chemotherapy-Induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Chemotherapy-Induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Chemotherapy-Induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Infection Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Infection Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Infection Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Stem Cell Transplant Support Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Stem Cell Transplant Support Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Stem Cell Transplant Support Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 35. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Inpatient Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Inpatient Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Inpatient Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Outpatient Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Outpatient Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Outpatient Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 48. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Academic Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Academic Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Academic Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Community Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Community Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Community Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 64. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Sargramostim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific Sargramostim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Asia-Pacific Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 73. Asia-Pacific Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 74. Asia-Pacific Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 75. Asia-Pacific Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 76. Asia-Pacific Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 77. Asia-Pacific Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 78. Asia-Pacific Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 79. Asia-Pacific Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 80. Asia-Pacific Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 81. North America Sargramostim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. North America Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 83. North America Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 84. North America Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 85. North America Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 86. North America Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 87. North America Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 88. North America Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. North America Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 90. North America Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 91. Latin America Sargramostim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Latin America Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 93. Latin America Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 94. Latin America Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 95. Latin America Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 96. Latin America Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 97. Latin America Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 98. Latin America Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 99. Latin America Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 100. Latin America Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 101. Europe Sargramostim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Europe Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 103. Europe Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 104. Europe Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 105. Europe Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 106. Europe Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 107. Europe Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 108. Europe Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 109. Europe Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 110. Europe Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 111. Middle East Sargramostim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 112. Middle East Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 113. Middle East Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 114. Middle East Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 115. Middle East Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 116. Middle East Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 117. Middle East Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 118. Middle East Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 119. Middle East Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 120. Middle East Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 121. Africa Sargramostim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 122. Africa Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 123. Africa Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 124. Africa Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 125. Africa Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 126. Africa Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 127. Africa Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 128. Africa Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 129. Africa Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 130. Africa Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 131. Global Sargramostim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 132. ASEAN Sargramostim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 133. ASEAN Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 134. ASEAN Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 135. ASEAN Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 136. ASEAN Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 137. ASEAN Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 138. ASEAN Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 139. ASEAN Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 140. ASEAN Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 141. ASEAN Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 142. GCC Sargramostim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 143. GCC Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 144. GCC Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 145. GCC Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 146. GCC Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 147. GCC Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 148. GCC Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 149. GCC Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. GCC Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 151. GCC Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 152. European Union Sargramostim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. European Union Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 154. European Union Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 155. European Union Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 156. European Union Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 157. European Union Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. European Union Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 159. European Union Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 160. European Union Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 161. European Union Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 162. BRICS Sargramostim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 163. BRICS Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 164. BRICS Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 165. BRICS Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 166. BRICS Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 167. BRICS Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 168. BRICS Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 169. BRICS Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 170. BRICS Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 171. BRICS Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 172. G7 Sargramostim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 173. G7 Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 174. G7 Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 175. G7 Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 176. G7 Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 177. G7 Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 178. G7 Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 179. G7 Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 180. G7 Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 181. G7 Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 182. NATO Sargramostim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 183. NATO Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 184. NATO Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 185. NATO Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 186. NATO Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 187. NATO Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 188. NATO Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 189. NATO Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 190. NATO Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 191. NATO Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 192. Global Sargramostim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 193. United States Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 194. United States Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 195. United States Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 196. United States Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 197. United States Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 198. United States Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 199. United States Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 200. United States Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 201. United States Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 202. United States Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 203. Canada Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 204. Canada Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 205. Canada Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 206. Canada Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 207. Canada Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 208. Canada Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 209. Canada Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 210. Canada Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 211. Canada Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 212. Canada Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 213. Mexico Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 214. Mexico Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 215. Mexico Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 216. Mexico Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 217. Mexico Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 218. Mexico Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 219. Mexico Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 220. Mexico Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 221. Mexico Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 222. Mexico Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 223. Brazil Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 224. Brazil Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 225. Brazil Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 226. Brazil Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 227. Brazil Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 228. Brazil Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 229. Brazil Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 230. Brazil Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 231. Brazil Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 232. Brazil Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 233. United Kingdom Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 234. United Kingdom Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 235. United Kingdom Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 236. United Kingdom Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 237. United Kingdom Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 238. United Kingdom Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 239. United Kingdom Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 240. United Kingdom Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 241. United Kingdom Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 242. United Kingdom Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 243. Germany Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 244. Germany Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 245. Germany Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 246. Germany Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 247. Germany Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 248. Germany Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 249. Germany Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 250. Germany Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 251. Germany Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 252. Germany Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 253. France Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 254. France Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 255. France Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 256. France Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 257. France Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 258. France Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 259. France Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 260. France Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 261. France Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 262. France Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 263. Russia Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 264. Russia Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 265. Russia Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 266. Russia Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 267. Russia Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 268. Russia Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 269. Russia Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 270. Russia Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 271. Russia Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 272. Russia Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 273. Italy Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 274. Italy Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 275. Italy Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 276. Italy Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 277. Italy Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 278. Italy Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 279. Italy Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 280. Italy Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 281. Italy Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 282. Italy Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 283. Spain Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 284. Spain Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 285. Spain Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 286. Spain Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 287. Spain Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 288. Spain Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 289. Spain Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 290. Spain Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 291. Spain Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 292. Spain Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 293. China Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 294. China Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 295. China Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 296. China Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 297. China Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 298. China Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 299. China Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 300. China Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 301. China Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 302. China Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 303. India Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 304. India Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 305. India Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 306. India Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 307. India Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 308. India Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 309. India Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 310. India Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 311. India Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 312. India Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 313. Japan Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 314. Japan Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 315. Japan Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 316. Japan Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 317. Japan Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 318. Japan Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 319. Japan Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 320. Japan Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 321. Japan Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 322. Japan Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 323. Australia Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 324. Australia Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 325. Australia Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 326. Australia Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 327. Australia Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 328. Australia Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 329. Australia Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 330. Australia Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 331. Australia Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 332. Australia Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 333. South Korea Sargramostim Market Size, 2017-2032 (USD Million)
  • TABLE 334. South Korea Sargramostim Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 335. South Korea Sargramostim Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 336. South Korea Sargramostim Market Size, by Mode Of Therapy, 2017-2032 (USD Million)
  • TABLE 337. South Korea Sargramostim Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 338. South Korea Sargramostim Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 339. South Korea Sargramostim Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 340. South Korea Sargramostim Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 341. South Korea Sargramostim Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 342. South Korea Sargramostim Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 343. Global Sargramostim Market Share, by Key Player, 2025
  • TABLE 344. Global Sargramostim Market, Key Experts